Sleep Apnea News and Research

RSS

Cortex second quarter net loss decreases to $356,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.

18 Aug 2011

CPAP withdrawal leads to return of obstructive sleep apnea

The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.

12 Aug 2011

Researchers develop epidermal electronic system

Through a combination of careful theoretical modeling and precise micro-manufacturing, a team of engineers and scientists has developed a new type of ultra-thin, self-adhesive electronics device that can effectively measure data about the human heart, brain waves and muscle activity - all without the use of bulky equipment, conductive fluids, or glues.

12 Aug 2011

Elderly women with sleep apnea more likely to develop dementia

Elderly women who suffer from sleep apnea -- characterized by disrupted breathing and sleep and a reduction in the intake of oxygen -- are about twice as likely to develop dementia in the next five years as those without the condition, according to a multi-center study led by researchers from the University of California, San Francisco.

10 Aug 2011

Older women with sleep disordered breathing may face greater risk of dementia

Older women who have sleep-related breathing problems may be at greater risk of problems with mental function, including dementia, according to a new study in the August 10, 2011 issue of the Journal of the American Medical Association.

10 Aug 2011

Continuous positive airway pressure machine more effective for sleep apnea patients

Among the treatments for obstructive sleep apnea, the effectiveness of a nighttime-breathing machine called a "CPAP" was backed by the strongest evidence, and a mouthpiece worn at night was also shown to be effective, according to a new report funded by HHS' Agency for Healthcare Research and Quality.

9 Aug 2011

VIVUS announces additional data from phase 3 QNEXA studies on obesity

VIVUS, Inc. today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV.

6 Aug 2011

Clinical warning system that uses wireless sensors can track vital signs of at-risk patients

A clinical warning system that uses wireless sensors to track the vital signs of at-risk patients is undergoing a feasibility study at Barnes-Jewish Hospital in St. Louis.

5 Aug 2011

Study: Compression stockings may improve OSA in patients with chronic venous insufficiency

Wearing compression stockings may be a simple low-tech way to improve obstructive sleep apnea in patients with chronic venous insufficiency, according to French researchers.

4 Aug 2011

FDA grants IDE approval for Apnex HGNS System to treat obstructive sleep apnea

Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation System to treat obstructive sleep apnea.

3 Aug 2011

Weight-loss programs a waste of time: Expert opinion

According to obesity expert and University of Melbourne professor of medicine Joseph Proietto the high failure rate of weight-loss programs could be explained by growing evidence that an obese person’s body is programmed to regain any weight that is lost. He said that authorities are wasting money on campaigns urging people to exercise and eat healthy food since obesity is “''physiologically defended”.

31 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Ventus Medical launches Provent Sleep Apnea Therapy in India

Ventus Medical is pleased to announce the Indian launch of its proprietary Provent Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea.

20 Jul 2011

Lap Band surgery less expensive than other obesity-related treatments

By being safe, minimally invasive, and extremely effective, the Lap Band has become one of the most accessible means for obese individuals with a BMI of 35 or higher to shed their excess weight and lead healthier lives.

16 Jul 2011

Severely obese children should be removed from parents, placed in care: Expert opinion

In a controversial new opinion piece in the Journal of the American Medical Association the authors suggest taking severely obese children out of their homes and placing them in foster care. Dr. David Ludwig, an obesity specialist at Harvard-affiliated Children’s Hospital Boston and Lindsey Murtagh, a lawyer and a researcher at Harvard’s School of Public Health, write that in some cases it may be justified to take an extremely obese child out of their parents’ custody.

13 Jul 2011

One-fifth of all patients with fatal pulmonary disease receive delayed diagnosis

One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers at Intermountain Medical Center in Salt Lake City.

12 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

NovaSom completes $35M equity financing led by Safeguard Scientifics

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for Obstructive Sleep Apnea (OSA) management, today announced it has closed $35 million in equity financing.

27 Jun 2011